{"organizations": [], "uuid": "f325a5069ee5b3aab193f38498ef74624ee86463", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-revance-provides-update-on-anticip/brief-revance-provides-update-on-anticipated-clinical-milestones-and-financial-outlook-for-2018-idUSASB0BZR6", "country": "US", "domain_rank": 408, "title": "BRIEF-Revance Provides Update On Anticipated Clinical Milestones And Financial Outlook For 2018", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-04T15:42:00.000+02:00", "replies_count": 0, "uuid": "f325a5069ee5b3aab193f38498ef74624ee86463"}, "author": "", "url": "https://www.reuters.com/article/brief-revance-provides-update-on-anticip/brief-revance-provides-update-on-anticipated-clinical-milestones-and-financial-outlook-for-2018-idUSASB0BZR6", "ord_in_thread": 0, "title": "BRIEF-Revance Provides Update On Anticipated Clinical Milestones And Financial Outlook For 2018", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters staff", "sentiment": "none"}, {"name": "revance therapeutics inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 44 PM / in 12 minutes BRIEF-Revance Provides Update On Anticipated Clinical Milestones And Financial Outlook For 2018 Reuters Staff \nJan 4 (Reuters) - Revance Therapeutics Inc: \n* REVANCE PROVIDES UPDATE ON ANTICIPATED CLINICAL MILESTONES AND FINANCIAL OUTLOOK FOR 2018 \n* REVANCE THERAPEUTICS INC - EXPECTS TO COMPLETE RT002 SAKURA PHASE 3 PROGRAM AND START RT002 PHASE 3 TRIAL FOR CERVICAL DYSTONIA IN 2018 \n* REVANCE THERAPEUTICS INC - EXPECTS CASH BURN FOR 2018 TO BE IN RANGE OF $117 TO $137 MILLION \n* REVANCE THERAPEUTICS INC - ANTICIPATES 2018 GAAP RESEARCH AND DEVELOPMENT EXPENSE TO BE IN RANGE OF $84 TO $101 MILLION Source text for Eikon:  ", "external_links": [], "published": "2018-01-04T15:42:00.000+02:00", "crawled": "2018-01-04T16:02:03.007+02:00", "highlightTitle": ""}